Healthcare resource use of patients with transthyretin amyloid cardiomyopathy.
Rosa Elisabeth LauppeJohan Liseth HansenAnna FornwallKatarina JohanssonMark H RozenbaumAnne Mette StrandMerja VakevainenJohanna KuusistoEinar GudeJ Gustav SmithFinn GustafssonPublished in: ESC heart failure (2022)
Transthyretin amyloid cardiomyopathy imposes a high burden on healthcare systems with twice as many outpatient specialist visits and 50% more hospitalizations in the year after diagnosis compared with HF patients without ATTR-CM. Studies to investigate if earlier diagnosis and treatment of ATTR-CM may lower resource use are warranted.